Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers

Introduction: RTS,S/AS01 is currently the most advanced malaria vaccine but provides incomplete, short-term protection. It was developed for use within the expanded program on immunizations (EPI) for African children. Another use could be adding mass RTS,S/AS01 vaccination to the integrated malaria...

Descripción completa

Detalles Bibliográficos
Autores principales: von Seidlein, Lorenz, Hanboonkunupakarn, Borimas, Jittamala, Podjanee, Pongsuwan, Pongphaya, Chotivanich, Kesinee, Tarning, Joel, Hoglund, Richard M., Winterberg, Markus, Mukaka, Mavuto, Peerawaranun, Pimnara, Sirithiranont, Pasathorn, Doran, Zoe, Ockenhouse, Christian F., Ivinson, Karen, Lee, Cynthia, Birkett, Ashley J., Kaslow, David C., Singhasivanon, Pratap, Day, Nicholas P.J., Dondorp, Arjen M., White, Nicholas J., Pukrittayakamee, Sasithon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012096/
https://www.ncbi.nlm.nih.gov/pubmed/31306084
http://dx.doi.org/10.1080/21645515.2019.1643675

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012096/
https://www.ncbi.nlm.nih.gov/pubmed/31306084
http://dx.doi.org/10.1080/21645515.2019.1643675

Ejemplares similares